1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030

Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030

  • March 2020
  • 111 pages
  • ID: 5875512
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Chronic Hand Eczema (CHE)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the CHE, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Chronic Hand Eczema (CHE) Disease Understanding
Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder exclusively localized to the hands. It is a highly prevalent, multi-etiological disease with a wide spectrum of severity and chronicity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance potentially damaging allergens and/or irritants.
Chronic Hand Eczema (CHE) has been defined as a long-lasting, relapsing course of Hand Eczema that is
• Disease duration of at least 3 months or more than 3 flares within the last 12 months,
• Unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months,
• The recurrence of symptoms two or more times within a year despite adequate treatment.
• No dominating active severe skin diseases or acute skin infections
CHE as an anatomoclinic syndrome with multifactorial origins that is not restricted to allergic or orthoergic origin. Clinical features include localization of eczema to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/blistering, fissures, pruritus, and pain. It is typically a dynamic condition extending over the years, and its morphology may change with time, both clinically and histologically. Erythema, edema, and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis, and fissures are seen in chronic eczema. It has significant morbidity and lost earnings and has severe negative impacts on the social and psychosocial aspects of patients’ lives.

Chronic Hand Eczema (CHE) Epidemiology
The CHE epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total diagnosed prevalent cases of Chronic Hand Eczema (CHE) patients 7MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted CHE symptoms epidemiology segmented as the Total prevalence of CHE, Gender-Specific cases of CHE, Diagnosed cases of CHE, Age-Specific cases of CHE, Severity Specific Cases of CHE and Subgroup Specific Cases of CHE. The report includes the prevalent scenario of CHE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017–2030.

Country Wise- Chronic Hand Eczema (CHE) Epidemiology
The epidemiology segment also provides the Chronic Hand Eczema (CHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
According to the report, The total prevalent population of CHE Associated in 7MM countries ranges from 4,229,215 in 2017.
• As per the estimates, United States has the highest prevalent population of CHE.
• Among the EU5 countries, Germany had the highest prevalent population of CHE, followed by France and the UK. On the other hand, Spain had the lowest prevalent population in 2017.
• On the other hand, Japan had 632,395 prevalent cases of Chronic Hand Eczema in 2017.

Scope of the Report
• The Chronic Hand Eczema (CHE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chronic Hand Eczema (CHE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Hand Eczema (CHE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Chronic Hand Eczema (CHE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of CHE
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Gender - specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Age-specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Sub group-specific Cases of Chronic Hand Eczema (CHE) in 7MM
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Diagnosed Cases of Chronic Hand Eczema (CHE) in 7MM
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Severity Specific Cases of Chronic Hand Eczema (CHE) in 7MM

Report Highlights

• 11-Year Forecast of Chronic Hand Eczema (CHE) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Chronic Hand Eczema (CHE)
• Prevalent Cases according to segmentation: Age-specific Prevalence of CHE
• Prevalent Cases according to segmentation: Gender-specific Prevalence of CHE
• Prevalent Cases according to segmentation: Diagnosed cases of CHE
• Prevalent Cases according to segmentation: Severity Specific cases of CHE
• Prevalent Cases according to segmentation: Subgroup Specific Cases of CHE

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHE?
• What are the key findings pertaining to the Chronic Hand Eczema (CHE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Chronic Hand Eczema (CHE) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the CHE?
• What are the currently available treatments of CHE?

Reasons to buy
The Chronic Hand Eczema (CHE) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Chronic Hand Eczema (CHE) market
• Quantify patient populations in the global Chronic Hand Eczema (CHE) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Hand Eczema (CHE) therapeutics in each of the markets covered
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Prevalence cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Gender-specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Age-specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Diagnosed- specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Severity - specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its subgroup-specific cases
• The Chronic Hand Eczema (CHE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Chronic Hand Eczema (CHE) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. The same number of estimation is found in the Thyssen et al., (2010) and others. Chronic Hand Eczema is estimated to occur in 5–7% of patients with Hand Eczema. As per Diepgen et al., Severe chronic HE has a major adverse impact on economic and social functions, with although abundant treatment options but with limited efficacy.
The chronic hand eczema registry on long-term patient management (CARPE) registry is the worldwide first registry of CHE that has been initiated in Germany which has a great contribution to health care research of chronic hand eczema. The CARPE was initiated in 2009, with the aim to investigate characteristics and treatment modalities in patients affected by chronic hand eczema in Germany. CARPE Registry-2015 found that mean disease duration was almost 8 years and CHE was graded as very severe or severe in approximately 70% of affected patients. Overall, 41% of patients had an atopic background and a type IV sensitization was reported in 48% of patients. Atopic hand eczema and allergic contact dermatitis were, however, reported in 34% and 22%.
Currently, register on patients with chronic hand eczema data from CARPE and a Swiss “sister-registry” showed that a significant proportion of patients may not receive adequate treatment according to guidelines. Future research will need to make use of longitudinal data to study the course of the disease and the effectiveness of different therapies in a comparative manner

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast – 2030

  • $ 3250
  • September 2020
  • 50 pages

“BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Majo ...

  • Europe
  • Japan
  • Dermatological Condition
  • Gene Therapy
  • Industry analysis
  • Health Expenditure

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on